BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 9165076)

  • 21. Cell-surface acceleration of urokinase-catalyzed receptor cleavage.
    Høyer-Hansen G; Ploug M; Behrendt N; Rønne E; Danø K
    Eur J Biochem; 1997 Jan; 243(1-2):21-6. PubMed ID: 9030717
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Crystal structure of the human urokinase plasminogen activator receptor bound to an antagonist peptide.
    Llinas P; Le Du MH; Gårdsvoll H; Danø K; Ploug M; Gilquin B; Stura EA; Ménez A
    EMBO J; 2005 May; 24(9):1655-63. PubMed ID: 15861141
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Urokinase induces proliferation of human ovarian cancer cells: characterization of structural elements required for growth factor function.
    Fischer K; Lutz V; Wilhelm O; Schmitt M; Graeff H; Heiss P; Nishiguchi T; Harbeck N; Kessler H; Luther T; Magdolen V; Reuning U
    FEBS Lett; 1998 Oct; 438(1-2):101-5. PubMed ID: 9821967
    [TBL] [Abstract][Full Text] [Related]  

  • 24. cDNA transfection of amino-terminal fragment of urokinase efficiently inhibits cancer cell invasion and metastasis.
    Zhu F; Jia S; Xing G; Gao L; Zhang L; He F
    DNA Cell Biol; 2001 May; 20(5):297-305. PubMed ID: 11410166
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibition of choroidal neovascularization by a peptide inhibitor of the urokinase plasminogen activator and receptor system in a mouse model.
    Das A; Boyd N; Jones TR; Talarico N; McGuire PG
    Arch Ophthalmol; 2004 Dec; 122(12):1844-9. PubMed ID: 15596589
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A new class of orthosteric uPAR·uPA small-molecule antagonists are allosteric inhibitors of the uPAR·vitronectin interaction.
    Liu D; Zhou D; Wang B; Knabe WE; Meroueh SO
    ACS Chem Biol; 2015 Jun; 10(6):1521-34. PubMed ID: 25671694
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Kinetics of reciprocal pro-urokinase/plasminogen activation--stimulation by a template formed by the urokinase receptor bound to poly(D-lysine).
    Petersen LC
    Eur J Biochem; 1997 Apr; 245(2):316-23. PubMed ID: 9151959
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Mechanism of tumor cell-induced extracellular matrix degradation--inhibition of cell-surface proteolytic activity might have a therapeutic effect on tumor cell invasion and metastasis].
    Kobayashi H
    Nihon Sanka Fujinka Gakkai Zasshi; 1996 Aug; 48(8):623-32. PubMed ID: 8808830
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Critical role of integrin alpha 5 beta 1 in urokinase (uPA)/urokinase receptor (uPAR, CD87) signaling.
    Tarui T; Andronicos N; Czekay RP; Mazar AP; Bdeir K; Parry GC; Kuo A; Loskutoff DJ; Cines DB; Takada Y
    J Biol Chem; 2003 Aug; 278(32):29863-72. PubMed ID: 12754207
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Glycosylation profile of a recombinant urokinase-type plasminogen activator receptor expressed in Chinese hamster ovary cells.
    Ploug M; Rahbek-Nielsen H; Nielsen PF; Roepstorff P; Dano K
    J Biol Chem; 1998 May; 273(22):13933-43. PubMed ID: 9593742
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Elevated urokinase-specific surface receptor expression is maintained through its interaction with urokinase plasminogen activator.
    Mahanivong C; Yu J; Huang S
    Mol Carcinog; 2007 Mar; 46(3):165-75. PubMed ID: 17186542
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Receptor-mediated regulation of plasminogen activator function: plasminogen activation by two directly membrane-anchored forms of urokinase.
    Vines DJ; Lee SW; Dichek DA; Ellis V
    J Pept Sci; 2000 Sep; 6(9):432-9. PubMed ID: 11016879
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ligand interaction between urokinase-type plasminogen activator and its receptor probed with 8-anilino-1-naphthalenesulfonate. Evidence for a hydrophobic binding site exposed only on the intact receptor.
    Ploug M; Ellis V; Danø K
    Biochemistry; 1994 Aug; 33(30):8991-7. PubMed ID: 8043585
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Urokinase-type plasminogen activation in three human breast cancer cell lines correlates with their in vitro invasiveness.
    Holst-Hansen C; Johannessen B; Høyer-Hansen G; Rømer J; Ellis V; Brünner N
    Clin Exp Metastasis; 1996 May; 14(3):297-307. PubMed ID: 8674284
    [TBL] [Abstract][Full Text] [Related]  

  • 35. One-step affinity purification of recombinant urokinase-type plasminogen activator receptor using a synthetic peptide developed by combinatorial chemistry.
    Jacobsen B; Gårdsvoll H; Juhl Funch G; Ostergaard S; Barkholt V; Ploug M
    Protein Expr Purif; 2007 Apr; 52(2):286-96. PubMed ID: 17027282
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Chemical modification of the urokinase-type plasminogen activator and its receptor using tetranitromethane. Evidence for the involvement of specific tyrosine residues in both molecules during receptor-ligand interaction.
    Ploug M; Rahbek-Nielsen H; Ellis V; Roepstorff P; Danø K
    Biochemistry; 1995 Oct; 34(39):12524-34. PubMed ID: 7548000
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Characterization of cell-associated plasminogen activation catalyzed by urokinase-type plasminogen activator, but independent of urokinase receptor (uPAR, CD87).
    Longstaff C; Merton RE; Fabregas P; Felez J
    Blood; 1999 Jun; 93(11):3839-46. PubMed ID: 10339491
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Plasminogen activation by pro-urokinase in complex with its receptor--dependence on a tripeptide (Spectrozyme plasmin).
    Wang J; Mazar A; Quan N; Schneider A; Henkin J
    Eur J Biochem; 1997 Jul; 247(1):256-61. PubMed ID: 9249034
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Epitope-mapped monoclonal antibodies as tools for functional and morphological analyses of the human urokinase receptor in tumor tissue.
    Luther T; Magdolen V; Albrecht S; Kasper M; Riemer C; Kessler H; Graeff H; Müller M; Schmitt M
    Am J Pathol; 1997 Apr; 150(4):1231-44. PubMed ID: 9094980
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Urokinase plasminogen activator amino-terminal peptides inhibit development of the rat ventral prostate.
    Elfman F; Bok R; Conn M; Shuman M; Cunha G
    Differentiation; 2001 Dec; 69(2-3):108-20. PubMed ID: 11798065
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.